ArticlePharmacoEconomics2021
Valuing SF-6Dv2 in Australia Using an International Protocol.
Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Health state values in cancer patients and the general population: evidence from SF-6Dv2.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.PharmacoEconomics · 2026Article
- Valuing health and wellbeing using discrete choice experiment: exploring feasibility, design effect and international preference similarity.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods.Health and quality of life outcomes · 2025Article
- Comparison of four approaches in eliciting health state utilities with SF-6Dv2.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities.Applied health economics and health policy · 2025Article
- Valuation survey for SF-6Dv2 in Japan based on the international protocol.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Health utility scores of six common cancers in China measured by SF-6Dv2.Health and quality of life outcomes · 2025Article
- The Short Form 6 Dimensions (SF-6D): Development and Evolution.Applied health economics and health policy · 2025Review
- Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China.Frontiers in oncology · 2025Article
- A Spanish value set for the SF-6D based on the SF-12 v1.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Valuing SF-6Dv2 Using a Discrete Choice Experiment in a General Population in Quebec, Canada.International journal of health policy and management · 2024Article
- QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia.Health and quality of life outcomes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SF-6Dv2 is an updated version of the SF-6D, with improved consistency and dimension descriptors, and value sets are required. The aim of this study was to estimate an SF-6Dv2 value set for Australia using an international protocol, while secondary aims were to compare Australian and UK values and to understand heterogeneity.
methodsThe study design was based on the SF-6Dv2 valuation protocol, which involved the administration of two different discrete choice experiment (DCE) tasks. The first task presented pairs of SF-6Dv2 health states with duration (Design 1), and the second task presented triplets that appended 'immediate death' to the health state pairs (Design 2). Respondents completed 12 choice sets online (10 from Design 1; 2 from Design 2). Value sets were estimated for Design 1 separately and combining Designs 1 and 2 using a variety of logit model specifications. Value set characteristics were compared descriptively with the UK model.
resultsThe sample included 3001 Australians. A range of ordered and consistent models were estimated. The models only including Design 1 data resulted in a relatively wider utility range. The value range was reduced by an interaction added when the health state included a dimension with a severe level. The model matched with the UK value set resulted in a larger utility range and consistent ordering of the most important dimensions.
conclusionThe model including the Design 1 data and moderating interaction was chosen for the Australian value set. This allows the SF-6Dv2 to be used in health technology assessment decision making in Australia.
Indexed as
Identifiers
34250578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.